CARDIAC SARCOMERE INHIBITORS
    1.
    发明申请

    公开(公告)号:WO2022187501A1

    公开(公告)日:2022-09-09

    申请号:PCT/US2022/018725

    申请日:2022-03-03

    摘要: Provided are compounds of Formula (I): or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1, R2, R3, and R4 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of using a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

    GRANULARITY ANALYSIS IN CELLULAR PHENOTYPES
    6.
    发明申请
    GRANULARITY ANALYSIS IN CELLULAR PHENOTYPES 审中-公开
    细胞分析中的细粒度分析

    公开(公告)号:WO2007081968A1

    公开(公告)日:2007-07-19

    申请号:PCT/US2007/000563

    申请日:2007-01-09

    摘要: Methods and apparatus, including computer program products, implementing and using techniques for analyzing images of cells and extraction of biologically significant features from the cell images, such as from granules representing intercellular organelles or other features in the images. In various embodiments, the extracted features can include the number of granules, the total surface area of the granules, the mean or maximum intensities of the granules, etc. These features can be determined on a cell-by cell basis, or for particular regions within a single cell, or for various groups of cells.

    摘要翻译: 方法和装置,包括计算机程序产品,用于分析细胞图像的实施和使用技术以及从细胞图像提取生物学显着特征,例如从表示细胞间细胞器的颗粒或图像中的其他特征。 在各种实施方案中,提取的特征可以包括颗粒的数量,颗粒的总表面积,颗粒的平均或最大强度等。这些特征可以基于逐个细胞或特定区域来确定 在单个细胞内,或用于各种细胞群。

    CERTAIN COMPOSITIONS AND METHODS OF TREATMENT

    公开(公告)号:WO2007067752A3

    公开(公告)日:2007-06-14

    申请号:PCT/US2006/046913

    申请日:2006-12-07

    IPC分类号: A01N43/16 A61K31/35

    摘要: Disclosed inter alia is the use of certain chromenone derivatives, which are modulators of a mitotic kinesin such as KSP, in the treatment of cellular proliferative diseases. The chromenones derivatives are administered with another chemotherapeutic agent selected from neutropenia treatment agents, alkylating agents, antimetabolites, platinating agents, topoisomerase inhibitors, tubulin agents and signalling inhibitors (e.g., kinase inhibitors). Pharmaceutical compositions comprising one or both types of active agents are also disclosed.